Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from Fidia Spa ( (IT:FDA) ) is now available.
Fidia S.p.A. has terminated its relationship with Dr. Luca Carante, who held the positions of Group Chief Financial Officer and Investor Relations Manager. This decision is part of a strategic move by the company’s top management to strengthen its organizational structure. In the interim, the CEO and Chairman of the Board will assume these roles until a suitable replacement is found. The company has initiated a selection process to appoint a new CFO and Investor Relations Manager, ensuring compliance with statutory and regulatory requirements.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.50 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
More about Fidia Spa
Fidia S.p.A., based in San Mauro Torinese, is a global leader in the design, production, and marketing of high-performance integrated milling systems. The company primarily serves the automotive and aerospace sectors, offering solutions that cover the entire milling process. With over 50 years of experience and approximately 133 employees, Fidia is recognized for its expertise in numerical controls, high-speed milling systems, and CAM software for complex shapes.
Average Trading Volume: 440,111
Technical Sentiment Signal: Strong Sell
Current Market Cap: €1.71M
For a thorough assessment of FDA stock, go to TipRanks’ Stock Analysis page.